Cardiotoxicity testing using pluripotent stem cell‐derived human cardiomyocytes and state‐of‐the‐art bioanalytics: a review

In this article, recent progress in cardiotoxicity testing based on the use of immortalized cell lines or human embryonic stem cell (hESC) derived cardiomyocytes in combination with state‐of‐the‐art bioanalytical methods and sensors is reviewed. The focus is on hESC‐derived cells and their refinement into competent testing cells, but the access and utility of other relevant cell types are also discussed. Recent developments in sensor techniques and bioanalytical approaches for measuring critical cardiotoxicity parameters are highlighted, together with aspects of data evaluation and validation. Finally, recommendations for further research are given. Copyright © 2011 John Wiley & Sons, Ltd.

[1]  Sean P. Palecek,et al.  Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.

[2]  M. Vos,et al.  Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[3]  C. Mummery,et al.  Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. , 2008, Differentiation; research in biological diversity.

[4]  C. Mandenius,et al.  A cell-based sensor system for toxicity testing using multiwavelength fluorescence spectroscopy. , 2009, Analytical biochemistry.

[5]  Carl-Fredrik Mandenius,et al.  Fluorescent cell-based sensing approaches for toxicity testing , 2010, Analytical and bioanalytical chemistry.

[6]  R. Zweigerdt,et al.  Cardiomyocyte enrichment from human embryonic stem cell cultures by selection of ALCAM surface expression. , 2009, Regenerative medicine.

[7]  Elmar Heinzle,et al.  Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. , 2011, Toxicology and applied pharmacology.

[8]  Oliver Frick,et al.  Hybrid optimization for 13C metabolic flux analysis using systems parametrized by compactification , 2008, BMC Systems Biology.

[9]  S. Harding,et al.  β1‐ and β2‐adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non‐failing adult human heart , 2008, British journal of pharmacology.

[10]  A. Higgins,et al.  Characterization of Human Embryonic Stem Cells by Cytogenetics: Karyotyping and Fluorescence In Situ Hybridization , 2010 .

[11]  Jean-Pierre Valentin,et al.  Reducing QT liability and proarrhythmic risk in drug discovery and development , 2010, British journal of pharmacology.

[12]  Giulio Cossu,et al.  Isolation and Expansion of Adult Cardiac Stem Cells From Human and Murine Heart , 2004, Circulation research.

[13]  Shmuel Einav,et al.  The effect of mechanical loads in the differentiation of precursor cells into mature cells , 2010, Annals of the New York Academy of Sciences.

[14]  Chris Denning,et al.  Transgenic enrichment of cardiomyocytes from human embryonic stem cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  G. Churchill,et al.  Characterization of human embryonic stem cell lines by the International Stem Cell Initiative , 2007, Nature Biotechnology.

[16]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[17]  Huei-Sheng Vincent Chen,et al.  Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. , 2010, Stem cells and development.

[18]  J. Itskovitz‐Eldor,et al.  Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. , 2003, American journal of physiology. Heart and circulatory physiology.

[19]  S. Nishikawa,et al.  A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.

[20]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[21]  Anders Lindahl,et al.  Cardiomyocyte clusters derived from human embryonic stem cells share similarities with human heart tissue. , 2010, Journal of molecular cell biology.

[22]  W. Claycomb,et al.  Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. , 2004, American journal of physiology. Heart and circulatory physiology.

[23]  J. Lexchin.  Drug withdrawals from the Canadian market for safety reasons, 1963–2004 , 2005, Canadian Medical Association Journal.

[24]  Carl-Fredrik Mandenius,et al.  Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. , 2010, Journal of biotechnology.

[25]  E. Sasaki,et al.  Nongenetic method for purifying stem cell–derived cardiomyocytes , 2010, Nature Methods.

[26]  C. Des Rosiers,et al.  Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. , 2004, American journal of physiology. Heart and circulatory physiology.

[27]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[28]  Robert Passier,et al.  Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[29]  Krishanu Saha,et al.  Designing synthetic materials to control stem cell phenotype. , 2007, Current opinion in chemical biology.

[30]  James A Thomson,et al.  Human Embryonic Stem Cells Develop Into Multiple Types of Cardiac Myocytes: Action Potential Characterization , 2003, Circulation research.

[31]  C. Mummery,et al.  Human stem cell models for predictive cardiac safety pharmacology. , 2010, Stem cell research.

[32]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[33]  L. Gepstein,et al.  Identification and selection of cardiomyocytes during human embryonic stem cell differentiation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  H. Kurosawa.  Methods for inducing embryoid body formation: in vitro differentiation system of embryonic stem cells. , 2007, Journal of bioscience and bioengineering.

[35]  A. Bruening-Wright,et al.  The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. , 2010, Journal of pharmacological and toxicological methods.

[36]  M. Tancer,et al.  Cardiac effects of MDMA on the metabolic profile determined with 1H‐magnetic resonance spectroscopy in the rat , 2009, NMR in biomedicine.

[37]  Michael Balls,et al.  The Role of Prevalidation in the Development, Validation and Acceptance of Alternative Methods , 1995 .

[38]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[39]  Jianhua Cheng.  Evidences of the gender‐related differences in cardiac repolarization and the underlying mechanisms in different animal species and human , 2006, Fundamental & clinical pharmacology.

[40]  U. Müller-Vieira,et al.  An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells. , 2009, Toxicology and applied pharmacology.

[41]  Ali Khademhosseini,et al.  Controlled-size embryoid body formation in concave microwell arrays. , 2010, Biomaterials.

[42]  P. Andrews,et al.  Culture and characterization of human embryonic stem cells. , 2004, Stem cells and development.

[43]  E. Heinzle,et al.  Mass spectrometry for metabolic flux analysis. , 1999, Biotechnology and bioengineering.

[44]  M. Kirk,et al.  Role of the Transverse‐Axial Tubule System in Generating Calcium Sparks and Calcium Transients in Rat Atrial Myocytes , 2003, The Journal of physiology.

[45]  J. Itskovitz‐Eldor,et al.  1,4,5‐Inositol Trisphosphate‐Operated Intracellular Ca2+ Stores and Angiotensin‐II/Endothelin‐1 Signaling Pathway Are Functional in Human Embryonic Stem Cell‐Derived Cardiomyocytes , 2008, Stem cells.

[46]  Christian Krause,et al.  Microplates with integrated oxygen sensors for kinetic cell respiration measurement and cytotoxicity testing in primary and secondary cell lines. , 2005, Assay and drug development technologies.

[47]  Masaki Ieda,et al.  Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. , 2010, Cell.

[48]  R. Pedersen,et al.  Human Embryonic Stem Cells as a Model for Studying Epigenetic Regulation During Early Development , 2005, Cell cycle.

[49]  Jarno M. A. Tanskanen,et al.  Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions—a comparison of multiple cell lines , 2009, Annals of medicine.

[50]  Ofer Binah,et al.  Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. , 2007, Journal of electrocardiology.

[51]  Bernhard O Palsson,et al.  Isotopomer analysis of myocardial substrate metabolism: A systems biology approach , 2006, Biotechnology and bioengineering.

[52]  T. Kennedy.  Managing the drug discovery/development interface , 1997 .

[53]  E. Bettiol,et al.  Developmental Changes in Cardiomyocytes Differentiated from Human Embryonic Stem Cells: A Molecular and Electrophysiological Approach , 2007, Stem cells.

[54]  Hua-rong Lu,et al.  Species Plays an Important Role in Drug‐Induced Prolongation of Action Potential Duration and Early Afterdepolarizations in Isolated Purkinje Fibers , 2001, Journal of cardiovascular electrophysiology.

[55]  G. Keller,et al.  Mechanisms of drug induced QT interval prolongation. , 2010, Current drug safety.

[56]  Dmitri B Papkovsky,et al.  Respirometric Screening Technology for ADME-Tox studies , 2006, Expert opinion on drug metabolism & toxicology.

[57]  B. Olsson,et al.  Regulation of 'stemness' and stem cell differentiation by microRNAs. , 2009, IDrugs : the investigational drugs journal.

[58]  G. Lyons,et al.  The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells. , 2010, Biomaterials.

[59]  B. Olsson,et al.  Molecular Signature of Cardiomyocyte Clusters Derived from Human Embryonic Stem Cells , 2008, Stem cells.

[60]  Robert Passier,et al.  Increased Cardiomyocyte Differentiation from Human Embryonic Stem Cells in Serum‐Free Cultures , 2005, Stem cells.

[61]  C. Mandenius,et al.  Monitoring of troponin release from cardiomyocytes during exposure to toxic substances using surface plasmon resonance biosensing , 2010, Analytical and bioanalytical chemistry.

[62]  E. Heinzle,et al.  High throughput, non-invasive and dynamic toxicity screening on adherent cells using respiratory measurements. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[63]  M. Goumans,et al.  Foetal and adult cardiomyocyte progenitor cells have different developmental potential , 2010, Journal of cellular and molecular medicine.

[64]  J. Hyllner,et al.  Differentiation of Human Embryonic Stem Cells to Cardiomyocytes for In Vitro and In Vivo Applications , 2010, Stem Cell Reviews and Reports.

[65]  J. Monshouwer-Kloots,et al.  Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. , 2010, Journal of proteome research.

[66]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[67]  Chunhui Xu,et al.  Characterization and Enrichment of Cardiomyocytes Derived From Human Embryonic Stem Cells , 2002, Circulation research.

[68]  J A Thomson,et al.  Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. , 2000, Developmental biology.

[69]  J. Hyllner,et al.  Derivation of a Xeno‐Free Human Embryonic Stem Cell Line , 2006, Stem cells.

[70]  The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NONCLINICAL EVALUATION OF THE POTENTIAL FOR DELAYED VENTRICULAR REPOLARIZATION (QT INTERVAL PROLONGATION) BY HUMAN PHARMACEUTICALS (C , 2004 .

[71]  K. Chien,et al.  Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511 , 2010, Nature Biotechnology.

[72]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[73]  N. Dalton,et al.  Phospholamban Ablation Rescues Sarcoplasmic Reticulum Ca2+ Handling but Exacerbates Cardiac Dysfunction in CaMKII&dgr;C Transgenic Mice , 2010, Circulation research.

[74]  M. Goumans,et al.  Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes , 2009, Expert opinion on drug discovery.

[75]  J. Lahann,et al.  Synthetic polymer coatings for long-term growth of human embryonic stem cells , 2010, Nature Biotechnology.

[76]  Ido Perlman,et al.  Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes , 2004, The Journal of physiology.

[77]  A. G. Fadeev,et al.  Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells , 2010, Nature Biotechnology.

[78]  Elmar Heinzle,et al.  Metabolic flux analysis in eukaryotes. , 2010, Current opinion in biotechnology.

[79]  P. Burridge,et al.  Improved Human Embryonic Stem Cell Embryoid Body Homogeneity and Cardiomyocyte Differentiation from a Novel V‐96 Plate Aggregation System Highlights Interline Variability , 2007, Stem cells.

[80]  K. Hornbuckle,et al.  Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .

[81]  K. Olejniczak,et al.  ICH Topic: The draft ICH S7B step 2: Note for guidance on safety pharmacology studies for human pharmaceuticals , 2002, Fundamental & clinical pharmacology.

[82]  J. Itskovitz‐Eldor,et al.  Functional Properties of Human Embryonic Stem Cell–Derived Cardiomyocytes: Intracellular Ca2+ Handling and the Role of Sarcoplasmic Reticulum in the Contraction , 2006, Stem cells.

[83]  Y. Yaron,et al.  Human embryonic stem cells carrying mutations for severe genetic disorders , 2010, In Vitro Cellular & Developmental Biology - Animal.

[84]  M. Schuldiner,et al.  Differentiation of Human Embryonic Stem Cells into Embryoid Bodies Comprising the Three Embryonic Germ Layers , 1999 .

[85]  Seung Jun Yoo,et al.  Enhanced differentiation of human embryonic stem cells into cardiomyocytes by combining hanging drop culture and 5-azacytidine treatment. , 2006, Differentiation; research in biological diversity.

[86]  W. Wiechert,et al.  Bidirectional reaction steps in metabolic networks: I. Modeling and simulation of carbon isotope labeling experiments. , 1997, Biotechnology and bioengineering.

[87]  E. Heinzle,et al.  Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2. , 2009, Toxicology and applied pharmacology.

[88]  E. Heinzle,et al.  Metabolic flux analysis gives an insight on verapamil induced changes in central metabolism of HL-1 cells. , 2011, Journal of biotechnology.

[89]  M. Tada,et al.  Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. , 2010, Stem cell research.

[90]  Antonio Zaza,et al.  Control of the cardiac action potential: The role of repolarization dynamics. , 2010, Journal of molecular and cellular cardiology.

[91]  Dmitri B Papkovsky,et al.  Methods in optical oxygen sensing: protocols and critical analyses. , 2004, Methods in enzymology.

[92]  W. Wiechert,et al.  Bidirectional reaction steps in metabolic networks: II. Flux estimation and statistical analysis. , 1997, Biotechnology and bioengineering.

[93]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[94]  Lila R Collins,et al.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.

[95]  Christoph Wittmann,et al.  Metabolic flux screening of Saccharomyces cerevisiae single knockout strains on glucose and galactose supports elucidation of gene function. , 2007, Journal of biotechnology.

[96]  V. Vedantham,et al.  Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors , 2010, Cell.

[97]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[98]  P. Sartipy,et al.  Molecular and Pharmacological Properties of Human Embryonic Stem Cell–Derived Cardiomyocytes , 2006, Experimental biology and medicine.

[99]  László Virág,et al.  Restricting Excessive Cardiac Action Potential and QT Prolongation: A Vital Role for IKs in Human Ventricular Muscle , 2005, Circulation.

[100]  M. Pekkanen-Mattila,et al.  A Defined and Xeno-Free Culture Method Enabling the Establishment of Clinical-Grade Human Embryonic, Induced Pluripotent and Adipose Stem Cells , 2010, PloS one.

[101]  L. Fink,et al.  Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts , 2009, Cell biology international.